Insider Selling: Invivyd, Inc. (NASDAQ:IVVD) Director Sells 150,000 Shares of Stock

Invivyd, Inc. (NASDAQ:IVVD) Director Terrance Mcguire sold 150,000 shares of Invivyd stock in a transaction on Monday, December 9th. The shares were sold at an average price of $0.61, for a total transaction of $91,500.00. Following the completion of the sale, the director now owns 4,538,079 shares in the company, valued at approximately $2,768,228.19. This trade represents a 3.20 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Terrance Mcguire also recently made the following trade(s):

• On Wednesday, December 11th, Terrance Mcguire sold 160,400 shares of Invivyd stock. The shares were sold at an average price of $0.59, for a total transaction of $94,636.00.

Invivyd Trading Down 5.7 %

Shares of Invivyd stock opened at $0.55 on Friday. The business has a fifty day simple moving average of $0.83 and a two-hundred day simple moving average of $1.07. The firm has a market capitalization of $65.43 million, a P/E ratio of -0.28 and a beta of 0.53. Invivyd, Inc. has a 12 month low of $0.54 and a 12 month high of $5.20.

Analyst Ratings Changes

Several analysts recently weighed in on IVVD shares. D. Boral Capital reiterated a “buy” rating and issued a $9.00 price target on shares of Invivyd in a report on Thursday, November 21st. HC Wainwright lowered their price objective on Invivyd from $15.00 to $10.00 and set a “buy” rating for the company in a research report on Wednesday, November 20th. Morgan Stanley lowered their price objective on Invivyd from $9.50 to $3.55 and set an “overweight” rating for the company in a research report on Wednesday, November 20th. Finally, EF Hutton Acquisition Co. I raised Invivyd to a “strong-buy” rating in a research report on Wednesday, October 30th. Four research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $7.89.

Hedge Funds Weigh In On Invivyd

Several large investors have recently modified their holdings of the stock. Vanguard Group Inc. raised its position in shares of Invivyd by 3.9% in the 1st quarter. Vanguard Group Inc. now owns 2,611,202 shares of the company’s stock worth $11,594,000 after purchasing an additional 97,496 shares during the last quarter. State Street Corp raised its position in shares of Invivyd by 3.7% in the 3rd quarter. State Street Corp now owns 1,018,640 shares of the company’s stock worth $1,039,000 after purchasing an additional 35,904 shares during the last quarter. Marshall Wace LLP raised its position in shares of Invivyd by 4.2% in the 2nd quarter. Marshall Wace LLP now owns 786,899 shares of the company’s stock worth $866,000 after purchasing an additional 31,992 shares during the last quarter. Acadian Asset Management LLC raised its position in shares of Invivyd by 232.0% in the 2nd quarter. Acadian Asset Management LLC now owns 678,706 shares of the company’s stock worth $745,000 after purchasing an additional 474,301 shares during the last quarter. Finally, Duquesne Family Office LLC purchased a new position in shares of Invivyd in the 2nd quarter worth about $629,000. Hedge funds and other institutional investors own 70.36% of the company’s stock.

Invivyd Company Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.